PLEASANTON, Calif.--(BUSINESS WIRE)--10x Genomics, a company focused on enabling the mastery of biology by accelerating genomic discovery, today announced its sponsorship of and participation in the 17th Annual Advances in Genome Biology and Technology (AGBT) Meeting, which is taking place February 13-16, in Hollywood Beach, Fla. In podium presentations, 10x Genomics scientists Deanna Church, Ph.D., senior director of applications, and Preyas Shah, Ph.D., research scientist, will discuss the growing opportunities for more complete genome analysis utilizing the company’s Linked-Read technology.
The company will also host a pre-conference symposium on Monday, February 13, featuring presentations by accomplished researchers using the Chromium System and software for whole-genome and exome sequencing (WGS and WES), de novo assembly, non-invasive prenatal testing (NIPT), stem-cell profiling, single-cell RNA-seq, and CRISPR research.
“For nearly two decades, AGBT has brought together scientists from around the world to discuss the latest advances in genome research,” said Dr. Church. “We are looking forward to hearing from researchers representing a diverse group of top-tier institutions who will discuss the cutting-edge science they are performing utilizing Linked-Read and single-cell data from the 10x Chromium System.”
The 10x Genomics Chromium™ System, which was announced last year at AGBT, features the company’s proprietary GemCode™ Technology to produce linked-read and single-cell RNA-seq (scRNA-seq) data from a user’s existing short-read sequencer. The Chromium System supports multiple applications, including:
- The Chromium™ Genome, Exome and de novo Assembly Solutions, which utilize the power of linked-read data to obtain multi-megabase genomic information from standard short-read sequencers. Linked-reads enable long-range haplotyping, structural variant calling, and access to previously inaccessible genomic information, as well as true diploid de novo assembly.
- The Chromium™ Single-Cell 3’ Solution is the first comprehensive commercial product for droplet-based scRNA-seq. The system, which since introduction last year at AGBT has become the industry leader for scalability and cost, enables massively parallel RNA-seq analysis of single cells (a few hundred) or even whole tissues ( >1 million cells) for gene expression experimentation at the scale and throughput needed to accomplish tissue and cell atlas studies.
“Over the past year, it’s been exciting to see how quickly our Linked-Read and Single-Cell Solutions have been able to provide researchers with access to crucial information not practically available through any other means. There has been an enormous diversity of research across applications, including clinical exome analysis, scRNA-seq analysis, NIPT and others, demonstrating the broad value of long-range and single-cell sequencing information in biomedical research,” said Dr. Saxonov.
In addition to presentations from Drs. Church (Tuesday, February 14, at 8:10 p.m. ET) and Shah (Wednesday, February 15, at 8:30 p.m. ET), poster presentations highlighting the use of Linked-Read and Single-Cell technologies from 10x Genomics will be delivered by researchers from The Broad Institute, Cold Spring Harbor Laboratory, Hudson Alpha Institute for Biotechnology, the New York Genome Center and the University of California, San Francisco.
Pre-Conference Symposium Details
The Company’s pre-conference symposium will feature multiple talks and roundtable discussions focused on the company’s Linked-Read and Single-Cell sequencing technologies and their broad suite of applications across exome, genome, and single-cell RNA-seq analyses. The symposium will take place on Monday, February 13, from 8 a.m.– 3 p.m. ET at the Diplomat Resort and Spa, Hollywood, Fla.
To register or learn more about the symposium, please visit: http://www.10xgenomics.com/event/agbt-pre-conference-symposium-hollywood-fl/.
About 10x Genomics
10x Genomics is changing the definition of sequencing by providing an innovative genomics platform that dramatically upgrades the capabilities of existing sequencing technologies. This is achieved through a combination of new microfluidic science, chemistry and bioinformatics. By implementing GemCode™ Technology within the Chromium™ System, researchers can now, for the first time, find new structural variants, haplotypes and other valuable genomic information with comprehensive workflows for Single Cell, Genome, Exome and de novo Assembly applications that incorporate the Company’s pre-existing sequencing technologies. www.10xGenomics.com.